We have studied the expression of the pituitary transcription factors Ptx-1 and Prop-1 in a series of 34 pituitary adenomas fully characterized for in vitro hormone secretion and histological staining. In studies involving mammalian cell lines, the pituitary transcription factor Ptx-1 has been shown to be a pituitary hormone panactivator, whereas more recent studies have shown that it plays an important role in ␣-subunit gene expression. Its expression has not been examined previously in human pituitary adenomas characterized by in vitro hormone secretory profiles. Of the 34 pituitary adenomas studied, Ptx-1 expression was reduced by more than 50% compared to that of the housekeeping gene human glyceraldehyde-3-phosphate dehydrogenase in the 6 corticotroph adenomas, which also had significantly reduced ␣-subunit production (all 6 tumors secreting Յ0.5 ng/24 h). Mutations of the pituitary transcription factor Prop-1, which is responsible for the syndrome of Ames dwarfism in mice, are being increasingly recognized as a cause of combined pituitary hormone deficiency in humans, although ACTH deficiency has been described only once. Prop-1 expression was detected in all 34 pituitary adenomas, including 6 corticotroph adenomas and 5 gonadotroph adenomas. The expression of Prop-1 has not been described previously in these cell phenotypes. (J Clin Endocrinol Metab 85: 2537-2542, 2000 T HE PITUITARY gland has a carefully orchestrated spatial and temporal sequence of hormone development in concert with DNA-binding trans-activating factors exerting control over the promoter elements of specific pituitary hormones to effect their cell specific expression (1-4). These cell-specific transcription factors may act either alone or in combination with other transcription factors to exert their tissue-specific action (1, 2). In an attempt to dissect out a role for pituitary transcription factors in pituitary tumorigenesis it seems logical to focus on transcription factors that are expressed at a very early stage in pituitary development. The first of these pituitary transcription factors, prophet of Pit-1
T HE PITUITARY gland has a carefully orchestrated spatial and temporal sequence of hormone development in concert with DNA-binding trans-activating factors exerting control over the promoter elements of specific pituitary hormones to effect their cell specific expression (1) (2) (3) (4) . These cell-specific transcription factors may act either alone or in combination with other transcription factors to exert their tissue-specific action (1, 2) . In an attempt to dissect out a role for pituitary transcription factors in pituitary tumorigenesis it seems logical to focus on transcription factors that are expressed at a very early stage in pituitary development. The first of these pituitary transcription factors, prophet of Pit-1 (Prop-1) (5), is involved in the transcription of GH, PRL, TSH␤, and LH/FSH genes and in the proliferation and differentiation of somatotrophs, lactotrophs, thyrotrophs, and gonadotrophs, but not corticotrophs (6 -8) . Mutations in the Prop-1 gene cause the syndrome of Ames dwarfism in mice and a similar phenotype in humans (7) (8) (9) . Previous studies in patients who have mutations in the Prop-1 gene demonstrate that phenotypic characteristics of the gene mutation in affected families are highly variable, but all demonstrate to some degree GH, PRL, TSH, LH, and FSH deficiencies as well as lower LH, FSH (7) (8) (9) , and ACTH levels in the circulation (10), a finding not present in Pit-1 gene mutations.
Constitutively active gene mutations in pituitary transcription factors have not been described to date in pituitary adenomas, and a connection between phenotype expression in pituitary ontogeny and actual hormone hypersecretion remains tenuous. Nevertheless, in light of a previous observation suggesting no difference in Prop-1 expression in a limited variety of pituitary adenomas (11), we sought to examine the expression of this transcription factor in a large series of pituitary adenomas, including corticotroph and gonadotroph adenomas (not previously studied), for which there was full histological and in vitro characterization of tumor phenotype.
The second transcription factor whose role we have studied in pituitary tumorigenesis, Ptx-1 (pituitary homeobox 1), had first been identified as being centrally linked to corticotroph expression, exerting cell-specific transcription of POMC in corticotrophs through interaction with the corticotroph upstream transcription element (12) . However, it is now clear that several pituitary-specific promoters or enhancers contain at least one putative Ptx-1-binding site (13, 14) , including those for ␣-subunit (␣-SU) (13) ; the ␤-subunits of LH, FSH, TSH, GH, the Pit-1 enhancer (15); as well as the POMC promoter (12) . Ptx-1 had been shown previously to be present at high levels in a subset of adult mouse anterior pituitary cells that express POMC (12) . However, recent pa-pers associate Ptx-1 expression more closely with ␣-SUproducing cell subtypes (16) .
Studies using Ptx-1 antisense ribonucleic acid (RNA) to generate Ptx-1 knockdown in ␣T3-1 cell lines demonstrated little or no ␣-SU messenger RNA (mRNA) expression in such cell lines (14) . The predominant expression of Ptx-1 protein in ␣-SU-positive cells (16) correlates with the higher expression of Ptx-1 protein and mRNA seen in thyrotroph, gonadotroph, and somatolactotroph cell lines compared to that in a corticotroph cell line (14) .
Recently, it has been shown that Ptx-1 is expressed in pituitary adenomas as well as normal adult pituitary cells (17) . However, in that study Ptx-1 expression was not correlated with in vitro data on hormone secretion. The present report concerns the direct comparison of ␣-SU and pituitary hormone secretion with Ptx-1 and Prop-1 mRNA expression in secretory and nonfunctioning (so-called null cell) pituitary adenomas. To this end, we performed studies in a large series of pituitary tumors for which we had full in vitro and immunohistochemical data and correlated the expression of these transcription factors with in vitro hormone release in each pituitary tumor.
Subjects and Methods

Clinical details and patient selection
Pituitary tumors were collected from patients at the time of transsphenoidal adenomectomy. Tissues were divided at the time of surgery for diagnostic histological studies and for tissue culture.
Acromegaly was diagnosed on the basis of persistently measurable GH and inadequate suppression on administration of an oral glucose load. Patients with corticotroph adenomas presented with typical clinical and biochemical features of cortisol excess. A pituitary source of ACTH hypersecretion was confirmed by inferior petrosal venous sampling. Those patients with presumed lactotroph macroadenomas represented a subset of patients with hyperprolactinemia that had not responded to treatment with dopamine agonist therapy and required debulking surgery before external beam radiotherapy. Patients who presented due to mass effect, without clinical features of pituitary hormone secretion, and with LH/FSH levels inappropriately low for the level of their gonadal steroids were classified as clinically nonfunctioning pituitary adenomas (NFPAs). In NFPAs with PRL hypersecretion, all had PRL easily suppressed to below assay detection limits with low dose dopamine agonist therapy. The diagnosis of prolactinoma was on the basis of clinical features of PRL hypersecretion with raised serum PRL above 1000 mU/L that was not easily suppressed to below the hormone assay detection limit by low dose dopamine agonist therapy. Furthermore, all clinical prolactinomas subsequently had diagnosis confirmed on tumor removal (all tumors stained strongly positive on immunostaining with PRL antibody and secreted elevated in vitro levels of PRL). After surgery, all tumors were classified according to their morphological and immunocytochemical characteristics by light microscopy. Tumors were excluded from the series if microscopy suggested an alternative histological diagnosis, if significant normal pituitary tissue was present on microscopy, or if the tissue appeared necrotic. We also excluded tumors in which ACTH was present in the culture medium in the absence of a clinical diagnosis of corticotroph adenoma, suggesting contamination with normal tissue. NFPAs all stained negative for PRL and were subsequently classified as being gonadotroph adenomas if they demonstrated strong immunocytochemical staining for LH␤ and/or FSH␤. The remainder of NFPAs were classified as being null cell adenomas, including those that demonstrated positivity for ␣-SU alone.
Morphology and immunocytochemistry
All tumors were examined by standard hematoxylin and eosin, reticulin, and periodic acid-Schiff stains, and routine immunostaining was performed for GH, PRL, ACTH, TSH, LH, FSH (antibodies against the whole molecule obtained from BioGenex Laboratories, Inc., Berks, UK), and ␣-SU (rabbit polyclonal, UCB Bioproducts, Braine-L'Alleud, Belgium) using a standard streptavidin-biotin-horseradish peroxidase method. The distinction between normal pituitary gland and tumor was confirmed by reticulin staining in all cases. The amount of positivity in all tumors was initially assessed and was quantified by means of a three-point scale (Ϫ, negative or scattered cells representing Ͻ10%; ϩ, 10 -50% positive; ϩϩ, Ͼ50%; Table 1 ) (24).
Pituitary tumor cell culture
Pituitary adenoma tissue was transported to the laboratory in DMEM containing 10% (vol/vol) heat-inactivated FCS, 0.06 g/L penicillin, 0.1 g/L streptomycin, and 2.5g/L fungizone (Life Technologies, Inc., Paisley, U.K.) and buffered with HEPES (0.02 mol/L), hereafter referred to as culture medium. Tumor tissue was dispersed enzymatically with trypsin as described previously (18) . Dispersed cells were harvested by centrifugation, washed once, and subsequently resuspended in culture medium. Cell viability was assessed using trypan blue exclusion and was more than 90% in all of the tumors studied after cell dispersion. Cell yield from each tumor varied from 1-15 ϫ 10 6 cells. The cells were plated in six-well plates at approximately 1 ϫ 10 6 cells/well in 4 mL medium. Cultures were incubated at 37 C in a humidified atmosphere of 95% air and 5% CO 2 for 48 h to allow cell attachment to occur, after which time the medium was collected and assayed for basal hormone secretion as described below. Adherent cells were lysed with a buffered guanidinium thiocyanate solution and stored at Ϫ70 C before mRNA extraction (see below).
mRNA analysis
Cell extract from cultured cells was thawed on ice and centrifuged to remove cell debris. mRNA was extracted according to a standard technique (Pharmacia Biotech, Uppsala, Sweden) using oligo(deoxythymidine)-cellulose and washed first with 0.5 mol/L NaCl (high salt) and then with 0.1 mol/L NaCl (low salt), each containing 10 mmol/L TrisHCl (pH 7.5) and buffered with 1 mmol/L ethylenediamine tetraacetate. Bound polyadenylated RNA was further washed with low salt buffer in a MicroSpin column (Pharmacia Biotech) and then eluted in 10 mmol/L Tris-HCl (pH 7.5) with 1 mmol/L ethylenediamine tetraacetate. mRNA was recovered by precipitation with glycogen (0.25 mg/mL) and 0.25 mol/L potassium acetate (pH 5.0) and centrifugation in 95% ethanol at Ϫ20 C. Quantitation was performed by measurement of absorbance at OD 260 ; approximately 0.5-1.0 g mRNA was extracted/10 6 cells. After denaturation at 65 C, first strand complementary DNA (cDNA) synthesis was catalyzed by Moloney murine leukemia virus reverse transcriptase using a NotI-(deoxythymidine) 18 bifunctional primer with a first strand cDNA biosynthesis kit (Pharmacia Biotech). PCR was carried out using the equivalent of 0.1 g mRNA in a volume of 50 L using 200 nmol/L deoxy-NTPs. Primers were designed from GenBank sequences [for Ptx-1, NM 002653; for Prop-1, AF 076215; for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), NM 002046; for primers and PCR conditions, see Table 1 ]. Primers were designed to span introns. For Prop-1 an initial PCR amplification series was performed, and a subsequent set of amplification reactions using a second set of primers was used to amplify the first Prop-1 PCR amplification product (diluted 1:1000). This was necessary because of the very low level of expression of Prop-1 in all of the pituitary adenomas. After optimization of PCR conditions for each primer pair, comparative kinetic analyses (19, 20) were performed to determine the phase during which there was an exponential increase in PCR product before a plateau was reached. It was at this point that the PCR was terminated, allowing comparative data to be obtained.
Negative controls included mock amplification of cDNA in the absence of template with the same PCR reaction mix. To ensure that were was no genomic contamination in the subsequent PCR reactions, a control reverse transcriptase reaction of tumor mRNA was performed in the absence of Moloney murine leukemia virus reverse transcriptase. This failed to amplify Ptx-1 or Prop-1 subsequently. The integrity of RNA from each specimen was verified in each reaction by PCR using GAPDH primers (Table 1) .
The size of the predicted product was visualized by 1.6% agarose gel electrophoresis with ethidium bromide staining. By performing serial dilutions of known quantity starting mRNA it was possible to determine that there was a linear relationship between starting mRNA and the optical density of the PCR band generated. Confirmation of Prop-1 and Ptx-1 products was confirmed by direct DNA sequencing.
Hormone assays
GH, PRL, LH, FSH, and TSH were measured using two-site chemiluminescent enzyme immunometric assays on the Immulite autoanalyzer (Euro/DPC Ltd., Gwenedd, UK). The intra-and interassay coefficients of variation for all of these assays are less than 6% and 10%, respectively. ACTH was measured by a specific double antibody RIA (Euro/DPC Ltd.) with inter-and intraassay coefficients of variation of less than 10%. ␣-SU concentrations were measured by a direct double antibody RIA using antibodies purchased from UCB Bioproducts (Brussels, Belgium) and chloramine-T-iodinated antigen (National Institute for Biological Standards and Control reagent 76/508, Potters Bar, UK) and were calibrated against First International Reference Preparation ND, Not determined.
75/569 (National Institute for Biological Standards and Controls)
. Intraand interassay coefficients of variation were less than 6% and less than 11%, respectively. Cross-reactivities (nanograms per nanogram) with purified LH, FSH, and TSH were 3.6%, 1.9%, and 1.3%, respectively. The detection limits of the above assays, defined as the concentration 2 sd above the response at zero dose, were as follows: GH, 0.5 mU/L; PRL, 10 mU/L; LH, 0.4 IU/L; FSH, 0.6 IU/L; TSH, 0.008 mU/L; ACTH, 4 pmol/L; and ␣-SU, 0.1 g/L. All samples from each individual tumor were analyzed in the same assay. Hormone data were initially obtained as concentrations, but were then corrected for cell number and incubation time. The data presented (Table 2 ) are therefore expressed as the amount of hormone secreted per 24 h/10 6 cells. The reported detection limits were as follows: GH, 2.0 U; PRL, 50 U; LH, 2.0 mIU; FSH, 3.0 mIU; TSH, 0.1 U; ACTH, 20 fmol; and ␣-SU, 0.5 ng.
Statistical analysis
All data are expressed as the mean Ϯ sd. Data for ␣-SU secretion comparison were compared by the Kruskall-Wallis test. Ptx-1 expression was compared by ANOVA followed by Tukey's multiple comparison test. Spearman rank correlation coefficients () were calculated to examine the correlations between the secretion of ␣-SU and Ptx-1 expression. For all tests, P Ͻ 0.05 was considered statistically significant.
Results
We examined Ptx-1 and Prop-1 expression in 34 patients for whom we had full clinical, histological, and in vitro data, allowing us to assign their pituitary tumors to the respective hormone-secreting groups. Pituitary tumors comprised 6 corticotroph, 8 somatotroph, 5 lactotroph, 5 gonadotroph (classified as described in methods section), 9 nonfunctioning, and 1 thyrotroph adenoma. These tumors were rigorously classified on histological and in vitro hormone expression as well as clinical grounds in all cases. The pituitary transcription factor, Prop-1, was examined in the above tumor groups. Prop-1 was expressed in all tumor types, including gonadotrophs (Fig. 3 shows a representative gel for Prop-1 expression). Due to the low level of Prop-1 expression, a seminested approach with a second reverse primer was used to analyze Prop-1 expression; it was not possible, therefore, to quantitate Prop-1 gene expression compared to that of a housekeeping gene as was done with Ptx-1. Nevertheless, we determined that Prop-1 was expressed in all pituitary adenomas including gonadotroph adenomas and all 6 corticotroph adenomas.
Ptx-1 expression (when expressed relative to the housekeeping gene GAPDH) was significantly lower in corticotroph tumors (0.45 Ϯ 0.12) compared to all other tumors combined (1.9 Ϯ 0.8; Fig. 1 ; P Ͻ 0.001). Ptx-1 expression was highest in the nonfunctioning and gonadotroph tumors, (2.2 Ϯ 0.3 and 2.3 Ϯ 0.3, respectively; Fig. 1 ; P Ͻ 0.05 for both compared to all other tumors).
Ptx-1 expression was examined in relation to ␣-SU secretion for all tumors and then correlated with ␣-SU expression for each tumor type. There was no relation between Ptx-1 expression and overall tumor ␣-SU secretion (Spearman correlation coefficient ϭ 0.2490; two-tailed P ϭ 0.1556). When each tumor type was examined separately for ␣-SU secretion, a different picture emerged, in that Ptx-1 expression was lowest in corticotrophs (P Ͻ 0.001), which also had the lowest ␣-SU secretion (P Ͻ 0.05), as confirmed by immunohistochemistry (Table 3 ). There was, however, no significant difference in ␣-SU secretion in the other tumor groups despite the significantly higher Ptx-1 expression in gonadotrophs and nonfunctioning tumors (Table 3 and Fig. 2 ). Ptx-1 expression did not correlate with the absence or presence of any other pituitary hormone in the tumors studied (data not shown). Representative gels of Prop-1 and Ptx-1 expression in human pituitary adenomas are shown (Figs. 3 and 4 , respectively). In summary, therefore, for the two transcription factors, Prop-1 and Ptx-1, Ptx-1 has a lower level of expression in corticotroph adenomas (associated with a lower level of ␣-SU secretion), whereas Prop-1 is ubiquitously expressed regardless of tumor phenotype, albeit at a low level of expression.
Discussion
It has previously been suggested that the pituitary transcription factor Ptx-1 is essential for POMC expression in Data are presented as means with SDs in parentheses for Ptx-1/GAPDH and medians with range in parentheses for ␣-SU. In the immunohistochemistry studies, data represent mean percent positivity with number of positive tumor/total number of tumors examined in parentheses. For the analysis of ␣-SU secretion, because the data did not conform to a normal distribution, nonparametric analysis was used. The P value represents the probability that all groups come from the same distribution (Kruskall-Wallis). For the analysis of Ptx-1 expression, data conformed to a normal distribution, and differences in means for the adenoma subtypes were compared by ANOVA.
a P Ͻ 0.001. b P Ͻ 0.05.
corticotrophs, binding to an upstream regulatory domain in the POMC gene (12) . It has subsequently been shown to be expressed in all pituitary hormone-secreting cell lines at the mRNA and protein levels (14) . It has also been suggested that Ptx-1 is an important transcription factor in ␣-SU expression, as evidenced by studies showing absent ␣-SU expression in Ptx-1-deficient cell lines (14) and stimulation of ␣-SU by Ptx-1 (13) . Studies in fetal mouse pituitary show Ptx-1 expression to be highest in ␣-SU-expressing tissue and to colocalize with ␣-SU (16) . In this study we show that Ptx-1 expression is diminished in corticotrophs compared to that in other tumor cell types, similar to ␣-SU secretion. However, there was no correlation between overall Ptx-1 expression and ␣-SU secretion in all pituitary tumors studied, making a specific effect of Ptx-1 on general ␣-SU gene transcription less likely. Nonetheless, it is of interest that both ␣-SU secretion and Ptx-1 expression were significantly diminished in corticotrophs.
Ptx-1 has previously been reported to have a strong stimulatory effect on ␣-SU promoter activity (13), where putative Ptx-1-binding sites have been located at bases Ϫ389 to 384 (13) (which may mediate most of the Ptx-1 activity) (14) and at Ϫ399 to Ϫ375 of the ␣-SU promoter (13) . This along with cell transfection work involving knockout of Ptx-1 expression in ␣-T3-1 cells, where ␣-SU gene expression was found to be absent, would seem to argue for a central role for Ptx-1 in ␣-SU expression. We examined the expression of both Ptx-1 and Prop-1 by RT-PCR analysis because of the difficulty in obtaining adequate amounts of tumor tissue by transsphenoidal surgery to quantitate by Northern blotting. The finding that Ptx-1 expression is significantly decreased in the corticotroph adenomas studied, which also have significantly lower ␣-SU secretion than all other pituitary tumor groups, is in agreement with a previous study showing diminished Ptx-1 expression in murine embryonic and adult pituitary cells that are ␣-SU negative on immunostaining (16) . Although ␣-SU synthesis in corticotroph tumors is not as uncommon as previously thought, being present on histological immunostaining in as many as 60% of true corticotroph adenomas (18), ␣-SU immunostaining was negative in all 6 corticotroph adenomas studied, and we speculate that the diminished Ptx-1 expression may be responsible for this decreased ␣-SU expression. Consistent with this hypothesis is the observation that in transgenic Ptx-1 knockout mice there is a marked reduction in ␣-SU expression (22) . There is no clear correlation between Ptx-1 expression and ␣-SU secretion, however, in pituitary tumor cells; the cell types with highest Ptx-1 expression (gonadotrophs and null cell tumors) having no higher ␣-SU secretion than other pituitary tumors as a whole. Nevertheless, it is possible that Ptx-1 expression above a threshold level is sufficient for ␣-SU synthesis in adult pituitary cells. Nakamura et al. recently described (11) the expression of Prop-1 in normal adult pituitary and in 14 pituitary adenomas. Their study was limited by the relatively small number of subjects examined (n ϭ 17), the lack of in vitro biochemical data, and the fact that only one corticotroph adenoma and no gonadotropin-secreting tumors were examined. These pituitary adenomas were not classified according to in vitro hormone secretion, thus making it difficult to ascribe with certainty a role for Prop-1 as a panhormonal transcription factor similar to Ptx-1. In the present study the finding that Prop-1 is expressed in all pituitary tumors examined (n ϭ 34), including all 6 corticotrophs and 6 gonadotroph adenomas (data not previously described) is consistent with previous literature documenting decreased ACTH (10) and gonadotroph reserve in patients suffering from homozygous mutations of the Prop-1 gene (7-9) and suggests that, at least in the adult pituitary, this transcription factor continues to be expressed in all pituitary cell types and may play a role in ACTH and gonadotroph expression as distinct from that of Pit-1. It may therefore activate transcriptional factors other than Pit-1. However, further studies are needed to elucidate this. In summary, we report that Prop-1 is expressed at low levels in all pituitary tumors, distinct from Ptx-1, which is specifically decreased in corticotroph tumors.
